TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Bergentoft Pharma Consulting AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
1,984
|
2,054 | |
| Financial expenses |
8
|
0 | |
| Earnings before taxes |
1,734
|
1,266 | |
| EBITDA |
1,718
|
1,266 | |
| Total assets |
3,979
|
2,938 | |
| Current assets |
3,024
|
1,938 | |
| Current liabilities |
626
|
766 | |
| Equity capital |
3,103
|
2,018 | |
| - share capital |
50
|
50 | |
| Employees (average) |
1
|
2
|
1 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
78.0%
|
68.7% | |
| Turnover per employee |
992
|
2,054 | |
| Profit as a percentage of turnover |
87.4%
|
61.6% | |
| Return on assets (ROA) |
43.8%
|
43.1% | |
| Current ratio |
483.1%
|
253.0% | |
| Return on equity (ROE) |
55.9%
|
62.7% | |
| Change turnover |
-70
|
878 | |
| Change turnover % |
-100%
|
-3%
|
75% |
| Chg. No. of employees |
-1
|
1
|
0 |
| Chg. No. of employees % |
-50%
|
100%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.